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Immunization of rhesus macaques with strains of simian immunodeficiency virus (SIV) that are limited to
a single cycle of infection elicits T-cell responses to multiple viral gene products and antibodies capable of
neutralizing lab-adapted SIV, but not neutralization-resistant primary isolates of SIV. In an effort to improve
upon the antibody responses, we immunized rhesus macaques with three strains of single-cycle SIV (scSIV)
that express envelope glycoproteins modified to lack structural features thought to interfere with the devel-
opment of neutralizing antibodies. These envelope-modified strains of scSIV lacked either five potential
N-linked glycosylation sites in gp120, three potential N-linked glycosylation sites in gp41, or 100 amino acids
in the V1V2 region of gp120. Three doses consisting of a mixture of the three envelope-modified strains of scSIV
were administered on weeks 0, 6, and 12, followed by two booster inoculations with vesicular stomatitis virus
(VSV) G trans-complemented scSIV on weeks 18 and 24. Although this immunization regimen did not elicit
antibodies capable of detectably neutralizing SIVmac239 or SIVmac251UCD, neutralizing antibody titers to the
envelope-modified strains were selectively enhanced. Virus-specific antibodies and T cells were observed in the
vaginal mucosa. After 20 weeks of repeated, low-dose vaginal challenge with SIVmac251UCD, six of eight
immunized animals versus six of six naïve controls became infected. Although immunization did not signifi-
cantly reduce the likelihood of acquiring immunodeficiency virus infection, statistically significant reductions
in peak and set point viral loads were observed in the immunized animals relative to the naïve control animals.
Development of a safe and effective vaccine for human im-
munodeficiency virus type 1 (HIV-1) is an urgent public health
priority, but remains a formidable scientific challenge. Passive
transfer experiments in macaques demonstrate neutralizing
antibodies can prevent infection by laboratory-engineered sim-
ian-human immunodeficiency virus (SHIV) strains (6, 33, 34,
53, 59). However, no current vaccine approach is capable of
eliciting antibodies that neutralize primary isolates with neu-
tralization-resistant envelope glycoproteins. Virus-specific T-
cell responses can be elicited by prime-boost strategies utilizing
recombinant DNA and/or viral vectors (3, 10, 11, 16, 36, 73, 77,
78), which confer containment of viral loads following chal-
lenge with SHIV89.6P (3, 13, 66, 68). Unfortunately, similar
vaccine regimens are much less effective against SIVmac239
and SIVmac251 (12, 16, 31, 36, 73), which bear closer resem-
blance to most transmitted HIV-1 isolates in their inability to
utilize CXCR4 as a coreceptor (18, 23, 24, 88) and inherent
high degree of resistance to neutralization by antibodies or
soluble CD4 (43, 55, 56). Live, attenuated SIV can provide
apparent sterile protection against challenge with SIVmac239
and SIVmac251 or at least contain viral replication below the
limit of detection (20, 22, 80). Due to the potential of the
attenuated viruses themselves to cause disease in neonatal
rhesus macaques (5, 7, 81) and to revert to a pathogenic phe-
notype through the accumulation of mutations over prolonged
periods of replication in adult animals (2, 35, 76), attenuated
HIV-1 is not under consideration for use in humans.
As an experimental vaccine approach designed to retain
many of the features of live, attenuated SIV, without the risk of
reversion to a pathogenic phenotype, we and others devised
genetic approaches for producing strains of SIV that are lim-
ited to a single cycle of infection (27, 28, 30, 38, 39, 45). In a
previous study, immunization of rhesus macaques with single-
cycle SIV (scSIV) trans-complemented with vesicular stomati-
tis virus (VSV) G elicited potent virus-specific T-cell responses
(39), which were comparable in magnitude to T-cell responses
elicited by optimized prime-boost regimens based on recom-
binant DNA and viral vectors (3, 16, 36, 68, 73, 78). Antibodies
were elicited that neutralized lab-adapted SIVmac251LA (39).
However, despite the presentation of the native, trimeric
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SIV envelope glycoprotein (Env) on the surface of infected
cells and virions, none of the scSIV-immunized macaques
developed antibody responses that neutralized SIVmac239
(39). Therefore, we have now introduced Env modifications
into scSIV that facilitate the development of neutralizing
antibodies.
Most primate lentiviral envelope glycoproteins are inher-
ently resistant to neutralizing antibodies due to structural and
thermodynamic properties that have evolved to enable persis-
tent replication in the face of vigorous antibody responses (17,
46, 47, 64, 71, 75, 79, 83, 85). Among these, extensive N-linked
glycosylation renders much of the Env surface inaccessible to
antibodies (17, 48, 60, 63, 75). Removal of N-linked glycans
from gp120 or gp41 by mutagenesis facilitates the induction of
antibodies to epitopes that are occluded by these carbohy-
drates in the wild-type virus (64, 85). Consequently, antibodies
from animals infected with glycan-deficient strains neutralize
these strains better than antibodies from animals infected with
the fully glycosylated SIVmac239 parental strain (64, 85). Most
importantly with regard to immunogen design, animals in-
fected with the glycan-deficient strains developed higher neu-
tralizing antibody titers against wild-type SIVmac239 (64, 85).
Additionally, the removal of a single N-linked glycan in gp120
enhanced the induction of neutralizing antibodies against
SHIV89.6P and SHIVSF162 in a prime-boost strategy by 20-fold
(50). These observations suggest that potential neutralization
determinants accessible in the wild-type Env are poorly immu-
nogenic unless specific N-linked glycans in gp120 and gp41 are
eliminated by mutagenesis.
The variable loop regions 1 and 2 (V1V2) of HIV-1 and SIV
gp120 may also interfere with the development of neutralizing
antibodies. Deletion of V1V2 from HIV-1 gp120 permitted
neutralizing monoclonal antibodies to CD4-inducible epitopes
to bind to gp120 in the absence of CD4, suggesting that V1V2
occludes potential neutralization determinants prior to the en-
gagement of CD4 (82). A deletion in V2 of HIV-1 Env-ex-
posed epitopes was conserved between clades (69), improved
the ability of a secreted Env trimer to elicit neutralizing anti-
bodies (9), and was present in a vaccine that conferred com-
plete protection against SHIVSF162P4 (8). A deletion of 100
amino acids in V1V2 of SIVmac239 rendered the virus sensitive
to monoclonal antibodies with various specificities (41). Fur-
thermore, three of five macaques experimentally infected with
SIVmac239 with V1V2 deleted resisted superinfection with
wild-type SIVmac239 (51). Thus, occlusion of potential neutral-
ization determinants by the V1V2 loop structure may contrib-
ute to the poor immunogenicity of the wild-type envelope
glycoprotein.
Here we tested the hypothesis that antibody responses to
scSIV could be improved by immunizing macaques with strains
of scSIV engineered to eliminate structural features that in-
terfere with the development of neutralizing antibodies. Anti-
bodies to Env-modified strains were selectively enhanced, but
these did not neutralize the wild-type SIV strains. We then
tested the hypothesis that immunization might prevent infec-
tion in a repeated, low-dose vaginal challenge model of het-
erosexual HIV-1 transmission. Indeed, while all six naïve con-
trol animals became infected, two of eight immunized animals
remained uninfected after 20 weeks of repeated vaginal chal-
lenge. Relative to the naïve control group, reductions in peak
and set point viral loads were statistically significant in the
immunized animals that became infected.
MATERIALS AND METHODS
Animals. The animals included in this study were all female Indian-origin
rhesus macaques (Macaca mulatta). They were housed in a biosafety level 3
containment facility at the New England Primate Research Center (NEPRC)
and given care in accordance with standards of the Association for Assessment
and Accreditation of Laboratory Animal Care and the Harvard Medical School
Animal Care and Use Committee. These experiments and procedures were
approved by the Harvard Medical Area Standing Committee on Animals and
were conducted in accordance with the Guide for the Care and Use of Laboratory
Animals (4).
The animals in this study were typed for the major histocompatibility complex
(MHC) class I alleles Mamu-A*01, -A*02, -A*08, -A*11, -B*01, -B*03, -B*04,
-B*08, -B*17, and -B*29, as well as the MHC class II alleles DRB1*w201,
DRB1*0401/06, and DPB1*06. The MHC typing results are summarized in Table
1. Typing was performed in David Watkins’ laboratory at the Wisconsin National
Primate Research Center (WNPRC), as previously described by Kaizu et al. (42).
Env-modified strains of scSIV. Mutations were introduced into the 3 half of
the SIVmac239 genome (40, 63, 85). A fragment containing a stop codon followed
by two single-nucleotide deletions in Nef (28) plus a stop codon at position E767
of Env was cloned into the NheI and SphI sites of the 3 halves of SIV genomes
TABLE 1. Typing for MHC class I and II alleles of the rhesus macaques selected for this studya
Group Animal
MHC class I allele MHC class II allele
A*01 A*02 A*08 A*11 B*01 B*03 B*04 B*08 B*17 B*29 DRB1*w201 DRB1*0401/06 DPB1*06
Immunized Mm 158-02             
Mm 234-99             
Mm 241-01             
Mm 259-03             
Mm 261-00             
Mm 284-99             
Mm 305-99             
Mm 316-98             
Naı¨ve Mm 358-01             
Mm 418-00             
Mm 128-01             
Mm 215-98             
Mm 214-04         
Mm 230-04         
a Allele-specific PCR was performed as described by Kaizu et al. (42).
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containing the M5, g123, and V1V2 Envs. Sequence tags gsa, cao, and ggr were
previously introduced into scSIV constructs containing the mutated frameshift
region and deletions in pol (23). SphI-SphI fragments of the 5 halves containing
the three sequence tags were cloned into the SphI sites of the 3 halves contain-
ing the M5, g123, and V1V2 Envs and stop codons in Env and Nef.
Preparation of scSIV. Virus stocks of scSIV were produced by cotransfection
of 293T cells with the Gag-Pol expression product pGPfusion and the proviral
DNA for each strain of scSIV (27). 293T cells were seeded on day 0 at a density
of 3  106 cells per 100-mm dish in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum (FBS), L-glutamine, pen-
icillin, and streptomycin. Cells were transfected on day 1 with 5 g of each
plasmid, using the GenJet transfection reagent according to the manufacturer’s
instructions (SignaGen Laboratories, Gaithersburg, MD). Medium was removed
on day 2, and cells were washed twice with serum-free DMEM, which was
replaced with DMEM supplemented with 10% rhesus serum (Equitech-Bio,
Kerrville, TX). Cell culture supernatant was collected on day 3. Cellular debris
was removed by centrifugation at 2,095  g, and supernatants were concentrated
by repeated, low-speed centrifugation in YM-50 ultrafiltration units (Millipore,
Bedford, MA), according to the manufacturer’s instructions. Aliquots of scSIV
were cryopreserved at 80°C until use. The virus concentration was determined
by SIV p27 antigen-capture enzyme-linked immunosorbent assay (ELISA) (Ad-
vance BioScience Laboratories, Kensington, MD).
Immunization of macaques with scSIV. Eight animals were inoculated intra-
venously with identical doses containing 5 g p27 of scSIVmac239M5,
scSIVmac239g123, and scSIVmac239V1V2 on weeks 0, 6, and 12. The animals
were boosted with 15 g p27 scSIVmac239 trans-complemented with VSV GNJ
(New Jersey serotype) on week 18 and 15 g p27 scSIVmac239 trans-comple-
mented with VSV GI (Indiana serotype) on week 24. Animals were anesthetized
by 15 mg/kg intramuscular injection of ketamine-HCl, and the concentrated
scSIV stock was injected through a 22-gauge catheter aseptically placed into the
saphenous vein.
Neutralizing antibodies. Neutralizing antibody titers were determined by mea-
suring the inhibition over serial, 2-fold plasma dilutions of the activity of a
secreted alkaline phosphatase (SEAP) reporter gene under transcriptional con-
trol of the SIV long terminal repeat (LTR) promoter in a C8166-derived T-cell
line (55). SEAP activity was measured using the Phospha-Light SEAP detection
kit (Applied Biosystems, Foster City, CA). Cells incubated without virus or
without plasma were used to determine the minimum and maximum SEAP
activities, respectively. The nearest values above and below 50% SEAP activity
were used to calculate what plasma dilution would intercept the 50% inhibition
line.
Virus was incubated with plasma dilutions in 100-l volumes for 1 h at 37°C
before addition of a 100-l volume containing the C8166-SEAP reporter cells.
Due to differences in infectivities between Env mutants, different amounts of
input virus and C8166-SEAP cells were used per well for each strain. Minimizing
the amount of input virus and time to reading SEAP activity maximizes the
apparent 50% neutralization titer (data not shown). These amounts and incu-
bation times were as follows: 12.5 ng p27 SIVmac239M5 and 50,000 cells, read on
day 5; 10 ng p27 SIVmac239g123 and 50,000 cells, read on day 4; 2.5 ng p27
SIVmac239V1V2 and 40,000 cells, read on day 3; 2 ng p27 SIVmac251LA and
15,000 cells, read on day 3; 0.5 ng p27 SIVmac239 and 15,000 cells, read on day
3; and 0.5 ng p27 SIVmac251UCD and 15,000 cells, read on day 3. SIVmac239M5,
SIVmac239g123, and SIVmac239 stocks were produced by transfection of 293T
cells. An uncloned SIVmac239V1V2 stock that was passed in herpesvirus
saimiri-transformed macaque 221 cells (40) and expanded in CD8-depleted,
phytohemagglutinin (PHA)-activated rhesus peripheral blood mononuclear cells
(PBMCs) was selected for the neutralizing antibody assays due to its higher
infectivity. SIVmac251LA was grown in MT4 cells. The SIVmac251UCD used for
neutralization assays was an uncloned stock, expanded from the challenge stock
for 5 days in CD8-depleted, PHA-activated rhesus PBMCs.
Collection and processing of mucosal specimens. Cervicovaginal and rectal
secretions were collected atraumatically with premoistened Weck-Cel sponges
(Medtronics, Minneapolis, MN) and extracted by centrifugation as previously
described (44). Vaginal biopsies containing both epithelium and underlying tis-
sue were collected using sterile pinch biopsy forceps. Lymphocytes were isolated
from biopsy specimens as previously described (29, 72). Biopsies were incubated
in 1 mM EDTA for 30 min at 37°C and then twice incubated for an hour in fresh
medium containing collagenase type IV while shaking vigorously. A cell suspen-
sion was obtained by mechanical dispersion of collagenase-treated samples with
a blunt-ended 18-G needle, followed by filtration using a 70-m-pore nylon cell
strainer. Cells were layered over a 35%/60% discontinuous Percoll gradient and
centrifuged for 20 min at 1,000  g to enrich for lymphocytes.
Mucosal antibodies. Concentrations of total IgG, total IgA, and antibodies to
gp120 and viral lysates were measured by chromagenic ELISA as previously
described (74), using microtiter plates coated with goat anti-monkey IgG (MP
BioMedicals, Solon, OH), goat anti-monkey IgA (Rockland, Gilbertsville, PA),
SIV mac251 rgp120 (ImmunoDiagnostics, Woburn, MA), or a 500-fold dilution of
SIV mac251 viral lysate (Advanced Biotechnologies Inc, Columbia, MD). The
viral lysate preparation contains undetectable levels of Env and is therefore
predominantly a measure of antibodies to Gag. Preparations of rhesus macaque
serum containing known quantities of each immunoglobulin or gp120-specific
antibody were used as standards. Prior to analyses for IgA antibodies, specimens
were depleted of IgG, using protein G-Sepharose as described previously (44).
Plates were developed with biotinylated goat anti-monkey IgA (Alpha Diagnos-
tics, San Antonio, TX) or anti-human IgG (Southern Biotech, Birmingham, AL)
polyclonal antibodies. The concentration of SIV-specific IgG or IgA in secretions
was normalized relative to the total IgG or IgA concentration by calculating the
specific activity (SA) (ng gp120-specific antibody per g total IgG or IgA). SA
values were considered to be significant if greater than the mean plus 3 standard
deviations of samples from naïve macaques.
IFN- ELISPOT assays. Longitudinal T-cell responses to Gag, Tat, Rev, Vif,
Vpr, Vpx, Env, and Nef were measured using pools of 15-mer peptides overlap-
ping by 11 residues at 2.5 g/ml. PBMCs were plated at 3  105 and 1  105 cells
per well in duplicate wells at each density on Multiscreen 96-well plates (Milli-
pore, Bedford, MA) and incubated overnight, and gamma interferon (IFN-)
was detected using the Mabtech enzyme-linked immunospot (ELISPOT) kit for
monkey/human IFN- (Mabtech, Mariemont, OH). Spots were enumerated by
an automated ELISPOT reader (Zellnet Consulting, New York, NY). The num-
ber of spot-forming cells (SFCs) per million PBMCs was calculated by subtract-
ing the number of background spots in wells that received cells but not peptide.
Full-proteome epitope mapping was expedited through the use of a deconvo-
lution matrix. Each animal was mapped using deconvolution matrices consisting
of one 96-well ELISPOT plate containing 92 matrix wells, three dimethyl sul-
foxide (DMSO)-only negative control wells, and one concanavalin A (ConA)-
positive control well. Peptides covering Gag, Pol, Tat, Rev, Vif, Vpr, Vpx, Env,
and Nef were each present in two of the 92 matrix wells. The matrix was designed
to minimize the number of potentially positive peptides that would require
individual testing. Mapping of CD4 T-cell epitopes was performed using
PBMCs depleted of CD8 cells by Dynal anti-CD8 magnetic beads (Invitrogen,
Carlsbad, CA). CD8 T-cell epitopes were mapped using PBMCs depleted of
CD4 cells. Depletions were conducted at a three-to-one bead-to-cell ratio for
45 min on a rotator at 4°C and confirmed by flow cytometry to have reduced the
target population to a maximum of 0.1% of lymphocytes. Cells were seeded to
the matrix plate at 1  105 cells per well. Surplus CD4- or CD8-depleted cells
were rested at 37°C overnight. After processing and enumeration of spots,
peptides present in two wells deemed positive, defined as greater than 50 SFCs
per million PBMCs and 3 standard deviations above background, were selected
for individual testing on the rested CD4- or CD8-depleted PBMCs.
MHC class I tetramer staining. MHC class I tetramer staining of virus-specific
CD8 T cells was conducted for the Mamu-A*01- and -A*02-positive macaques.
A 200-l volume of whole blood was incubated for 30 min at 37°C with one of
the allophycocyanin (APC)-conjugated tetramers Mamu-A*01 Gag181–189
(CM9), Mamu-A*01 Tat28–35 (SL8), Mamu-A*02 Nef159–167 (YY9), or Mamu-
A*02 Gag71–79 (GY9). These tetramers were provided by David Watkins’ labo-
ratory (WNPRC, Madison, WI). Samples were then stained for 30 min at room
temperature with fluorescein isothiocyanate (FITC)-conjugated anti-CD3 (clone
SP34; BD Biosciences, San Jose, CA) and peridinin chlorophyll protein (PerCP)-
conjugated anti-CD8 (clone SK1; BD Biosciences). Erythrocytes were then elim-
inated by treatment with fluorescence-activated cell sorter (FACS) lysing solu-
tion (BD Biosciences, San Jose, CA). Samples were washed and fixed in 2%
formaldehyde in phosphate-buffered saline (PBS). A FACSCalibur flow cytom-
eter was used for data collection (BD Biosciences, San Jose, CA). Data were
analyzed using the FlowJo, version 8.7.1, software package (Tree Star, San
Carlos, CA).
Repeated, low-dose vaginal challenge with SIVmac251UCD. The SIVmac251UCD
virus stock used for challenges was prepared at the California National Primate
Research Center in June 2004. We have adopted the “UCD” designation to
indicate that this virus stock has its own passage history, in PBMCs and in
monkeys, although it was derived from a SIVmac251 stock originally provided by
Ronald Desrosiers.
Fresh vials of virus were thawed at 37°C, transferred immediately to ice, and
diluted 1 to 100 in RPMI tissue culture medium (Invitrogen, Carlsbad, CA)
containing no additional additives. Each 1-ml dose contained 1 ng SIV p27
equivalents or 1,000 50% tissue culture infective doses (TCID50). Doses were
stored on ice until inoculation. Animals were anesthetized by a 15-mg/kg intra-
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muscular injection of ketamine-HCl and positioned with their hindquarters
raised for vaginal inoculation and for the following 30 min. Four hours later, the
above challenge procedure was repeated. Challenge days were spaced 1 week
apart and were discontinued once viral RNA was detectable in plasma for two
consecutive weeks.
Plasma viral RNA loads. Plasma samples were collected in 0.5- to 1.5-ml
volumes of sodium citrate anticoagulant and ultracentrifuged at 20,000  g for
1 h to pellet virus. RNA was extracted, reverse transcribed into cDNA, and
quantified by real-time PCR as previously described (19). The limit of detection
for this assay is 30 copies of RNA per ml. The primer/probe sets for the
quantitative, multiplex real-time reverse transcription (RT)-PCR assay for the
unique sequence tags ggr, cao, and gsa have previously been described by De-
Gottardi et al. (23).
CD4 T-cell subsets. The maintenance or destruction of naïve, central mem-
ory, effector memory, CCR5 memory, and total CD4 T-cell populations was
monitored by flow cytometry. Total CD4 T-cell counts and the concentrations
of each cell population per l whole blood were calculated by enumerating
lymphocytes per l of whole blood by complete blood count (CBC) and multi-
plying by the percentage belonging to each CD4 T-cell subpopulation as de-
termined by flow cytometry. Whole blood was stained with fluorescein isothio-
cyanate (FITC)-conjugated anti-CD3 (clone SP34; BD Biosciences, San Jose,
CA), PerCP-conjugated anti-CD4 (clone L200; BD Biosciences, San Jose, CA),
APC-conjugated anti-CD95 (clone DX2; BD Biosciences, San Jose, CA), and
phycoerythrin (PE)-conjugated anti-CD28 (clone CD28.2; BD Biosciences, San
Jose, CA) or PE-conjugated anti-CCR5 (clone 3A9; BD Biosciences, San Jose,
CA). Erythrocytes were eliminated with FACS lysing solution (BD Biosciences,
San Jose, CA), and cells were washed and fixed in 2% formaldehyde in PBS.
Flow cytometry data for CD4 T cells were collected and analyzed as described
for tetramer data.
Statistical methods. All statistical evaluations were conducted using SPSS 15.0
(SPSS, Inc., Chicago, IL) and Strata MP 10.0 (Strata Corp., College Station, TX).
The differences in the ratio of anti-gp120 IgG SA in CVS to plasma were
compared between the uninfected immunized animals (n  2) and those immu-
nized and infected (n  6) using a generalized estimation equation (GEE)
model. Correlations between repeated measurements within the same subject
were accounted for by use of unstructured covariance as well as first order
autocorrelation. Both approaches lead to a similar result. In total, 31 measure-
ments from eight animals were included.
A two-tailed Mann-Whitney U test on the highest measured log-transformed
values between weeks 1 and 5 postinfection was used to determine the signifi-
cance of differences in peak viral loads. A linear mixed model analysis was used
to determine the significance of differences in CD4 T-cell counts and log-
transformed set point viral loads between the immunized and naïve groups (25).
Set point viral loads were evaluated for the period between weeks 5 and 67
postinfection, centered on week 28.
RESULTS
Immunization of macaques with Env-modified strains of
scSIV. Rhesus macaques were immunized with three strains of
scSIV, each of which had different mutations that deprive the
SIV envelope glycoprotein of specific countermeasures against
host antibody responses. The wild-type SIVmac239 Env has 23
potential N-linked glycosylation sites in gp120 and 3 potential
N-linked glycosylation sites in gp41 (Fig. 1A). The 5th, 6th, 8th,
12th, and 13th potential N-linked glycosylation sites in gp120
were eliminated by mutagenesis in the Env-modified scSIV
strain scSIVmac239M5 (Fig. 1B) (64). All three potential N-
linked glycosylation sites in gp41 were eliminated in strain
scSIVmac239g123 (Fig. 1C) (85). The third Env-modified scSIV
strain, scSIVmac239V1V2, had 100 amino acids in the V1V2
loop structure deleted (Fig. 1D) (40). These three strains of
Env-modified scSIV also had a glutamate-to-stop codon
change to truncate the cytoplasmic tail of gp41, which maxi-
mizes Env incorporation onto virions, viral infectivity, and the
Env-specific antibody response (Fig. 1B to D) (23, 86). In order
to maximize CD8 T-cell responses, each scSIV strain con-
tained a premature stop codon in nef that eliminates 26 amino
acids from the C terminus of the protein required for MHC
class I downregulation (Fig. 1B to D) (70).
Eight female rhesus macaques received three intravenous
inoculations consisting of a mixture of 5 g p27 equivalents of
each of the three Env-modified scSIV strains on weeks 0, 6,
and 12 to prime antibody responses to Env surfaces with lim-
ited accessibility in the native trimer (Fig. 1E). These immu-
nogens would be expected to also prime antibody responses to
novel surfaces unique to the mutant Envs. Truncation of the
Env cytoplasmic tail can also alter the conformation of the
ectodomain (21, 26, 84, 86). Therefore, to focus the antibody
response on surfaces exposed in the native trimer, the animals
were boosted on weeks 18 and 24 with 15 g p27 equivalents
of scSIVmac239, which expresses the wild-type SIVmac239 Env
with a full-length cytoplasmic tail (Fig. 1E). These two booster
doses were trans-complemented with VSV G to maximize in-
fectivity. To prevent neutralization of the second boost by VSV
G-specific antibodies (39, 67), scSIV was trans-complemented
with the New Jersey serotype (VSV GNJ) on week 18, and the
Indiana serotype (VSV GI) on week 24. This immunization
regimen was designed to maximize the stimulation of both
Env-specific antibody responses and the magnitude of virus-
specific T-cell responses.
To determine whether this immunization regimen might re-
FIG. 1. Animals were immunized with Env-modified single-cycle
SIV and challenged by repeated, low-dose vaginal inoculation. A sche-
matic representation of the wild-type SIVmac239 Env appears at the
top (A). Positions of potential sites of N-linked glycosylation (N-X-S/T
motifs) are indicated by tree-like symbols. Features removed from
each Env-modified strain are indicated (red). The M5 Env has aspar-
agine-to-glutamine substitutions that eliminate the 5th, 6th, 8th, 12th,
and 13th potential N-linked glycosylation sites in gp120 (B). The g123
Env has all three potential N-linked glycosylation sites in gp41 similarly
eliminated (C). Variable loops 1 and 2 of the V1V2 envelope are
deleted (D). All of the modified envelopes have a glutamate-to-stop
codon change at position 767 (E767*). Eight macaques received an
intravenous injection consisting of a mixture of 5 g p27 equivalents of
scSIVmac239M5, scSIVmac239g123, and scSIVmac239V1V2 on weeks
0, 6, and 12 (E). All eight animals also received 15 g p27 equivalents
of VSV G trans-complemented scSIVmac239 intravenously on weeks 18
and 24. Beginning on week 32, the animals were challenged vaginally
with 1,000 TCID50 (1 ng p27) of SIVmac251UCD twice per day on the
same day each week for 20 weeks or until viral RNA was detected in
plasma on two consecutive weeks.
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duce the likelihood of viral transmission by the vaginal route,
the eight immunized animals and six naïve controls were re-
peatedly challenged for 20 weeks by low-dose vaginal inocula-
tion of SIVmac251UCD, beginning on week 32 (Fig. 1E). This
challenge regimen was expected to be sufficient to infect all the
naïve control animals (52). Thus, significant differences in the
number of doses required to establish infection or in the final
number of infections for the immunized versus naïve groups
might indicate that immunization reduced vaginal transmis-
sion.
Transient viremia following each dose of Env-modified and
VSV G trans-complemented scSIV. Transient viral loads in
plasma representing the progeny virions released by cells in-
fected with each Env-modified strain of scSIV were measured
independently using a quantitative, multiplex real-time RT-
PCR assay specific for unique sequence tags cloned into the pol
gene of each strain (23). Since cell-free virus is cleared from
plasma with a half-life on the order of just a few minutes (37,
87), these viral RNA load measurements reflect the life span of
cells productively infected with scSIV in vivo and thus the
duration of antigenic stimulation. The peaks of viremia for
scSIVmac239M5 and scSIVmac239g123 were nearly identical,
with geometric mean peak viral loads after the first inoculation
of 6.8  103 and 6.1  103 RNA copies per ml (Fig. 2).
However, peak viral loads for scSIVmac239V1V2 were con-
siderably lower than those of the two other Env-modified
strains, resulting in detectable viral loads in only four of the
eight immunized animals, the highest of which peaked at 170
copies of viral RNA per ml in Mm 158-02. Except for the first
dose of scSIVmac239M5 in Mm 316-98, all single-cycle viral
loads for each strain were cleared to below the limit of detec-
tion by 3 weeks after inoculation. Relative to the first dose,
peak viral loads were lower after the second inoculation for
both scSIVmac239M5 (P  0.0002) and scSIVmac239g123 (P 
0.0002). Following the booster inoculations with VSV GNJ and
VSV GI trans-complemented scSIV on weeks 18 and 24, peak
geometric mean viral loads were 1.8 104 and 7.8 103 copies
of viral RNA per ml, consistent with the infectivity enhance-
ment afforded by VSV G (39). These viral load measurements
confirm the productive infection of cells in vivo by the Env-
modified and VSV G trans-complemented strains of scSIV.
Neutralization of Env-modified and lab-adapted SIV, but
not wild-type SIVmac239 or SIVmac251UCD. To determine
whether immunization with the Env-modified strains of scSIV
significantly enhanced antibody responses to surfaces occluded
by the N-linked glycans and V1V2 loops, neutralization of the
Env-modified viruses by plasma samples from this study was
compared to neutralization by plasma samples from a previous
study, in which animals were immunized with strains of scSIV
expressing wild-type envelope glycoproteins from SIVmac239,
SIVmac316, and SIVmac155T3 (Fig. 3A to H) (39). The plasma
samples utilized for this comparison were collected 2 weeks
after the third intravenous inoculation with scSIV in both stud-
ies. Neutralization assays using plasma samples from both
studies were performed in parallel.
No significant difference was detected for neutralization of
SIVmac251LA by plasmas from the two groups (P  0.30; two-
tailed Mann-Whitney U test) (Fig. 3A and E). This suggests
that any differences in neutralizing antibody titers against the
Env-modified strains do not reflect nonspecific differences in
overall antibody titers between the two studies. All of the
animals immunized with Env-modified or wild-type strains of
scSIV neutralized SIVmac239M5, consistent with previous obser-
vations that elimination of these carbohydrate attachment sites
increases the susceptibility of this virus to neutralization (41, 64).
However, neutralizing antibody titers to SIVmac239M5 were not
significantly different for animals immunized with Env-modified
versus wild-type strains of scSIV (P  0.37; two-tailed Mann-
Whitney U test) (Fig. 3B and F), indicating that scSIVmac239M5
did not specifically facilitate the induction of antibodies to
epitopes occluded by the 5th, 6th, 8th, 12th, and 13th N-linked
glycans in gp120. In contrast, SIVmac239g123 was detectably neu-
tralized at low titers by only two of the animals immunized with
wild-type scSIV but was neutralized by all of the animals immu-
nized with the Env-modified strains of scSIV and at titers five
times higher (P 0.01; two-tailed Mann-Whitney U test) (Fig. 3C
and G). The difference in 50% neutralization titers between the
FIG. 2. Plasma viral RNA following each inoculation with single-
cycle SIV. The level of viral RNA in plasma was measured indepen-
dently for each of these strains using a quantitative, multiplex real-time
RT-PCR assay for the unique sequence tags ggr, cao, and gsa cloned
into each of the three scSIV strains (23). This assay has a threshold of
detection of 30 copies of viral RNA per ml plasma (dotted line).
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groups remains statistically significant even if the outlier, Mm
284-99, with a titer of 1:5,763 (nearly 200-fold higher than the
average for the rest of the group), is excluded from the analysis
(P 0.02). These results suggest that the N-linked glycans in gp41
interfere with the induction of Env-specific antibody responses
and that the elimination of these glycans by mutagenesis can
enhance the induction of antibodies to surfaces accessible in this
N-linked glycan-deficient strain.
Immunization with Env-modified strains also elicited higher
neutralizing antibody titers to the virus with V1V2 deleted
than did scSIV expressing wild-type Envs. While plasma from
animals immunized with either the Env-modified or wild-type
strains of scSIV both neutralized SIVmac239V1V2, titers for
the animals immunized with Env-modified strains were seven
times higher (P  0.01; two-tailed Mann-Whitney U test) (Fig.
3D and H). Indeed, the animals immunized with Env-modified
scSIV were all able to neutralize SIVmac239V1V2 infectivity
to 	2% and had 50% neutralization titers that ranged from
3.1  103 to 8.4  104. Thus, in spite of the comparably poor
take of infection by scSIVmac239V1V2 (Fig. 2), immunization
with Env-modified scSIV enhanced the induction of antibodies
to determinants revealed by deletion of the V1V2 loops.
Although immunization with Env-modified strains of scSIV
enhanced the induction of antibodies that neutralize
SIVmac239g123 and SIVmac239V1V2, plasma samples col-
lected 2 weeks after the third dose of Env-modified scSIV
(week 14) and 2 weeks after the second VSV G scSIV boost
(week 26) failed to detectably neutralize SIVmac239 (Fig. 3I
and J). Likewise, plasma collected on the first day of challenge
(week 32) did not detectably neutralize the SIVmac251UCD
challenge strain (Fig. 3K).
SIV-specific antibodies in mucosal secretions. Mucosal se-
cretions were tested for SIV-specific antibodies before and
after challenge (Fig. 4). Vaginal and rectal secretions were
collected using premoistened Weck-Cel sponges to avoid abra-
sion of the mucosal epithelium (44). This approach permits the
nearly exclusive collection of secretions, without drawing fluid
from the underlying tissue (44). To control for significant vari-
ability in the concentrations of total IgG and IgA in mucosal
secretions over time and over the menstrual cycle, the specific
activity (SA) of antibody titers to gp120 or viral lysates was
calculated by dividing the g amount of SIV-specific antibody
by the mg amount of total IgG or IgA in the sample (Fig. 4).
Gp120-specific IgG was detectable in the cervicovaginal se-
FIG. 3. Plasmas neutralized Env-modified and lab-adapted SIV but not wild-type SIV. Neutralizing antibody titers were compared between the
animals immunized with Env-modified scSIV that subsequently became infected (blue) or remained uninfected (green) and historical control
plasmas from animals immunized with scSIV expressing wild-type Envs (black). Pooled preimmune plasma served as a negative control (gray). The
dotted line indicates 50% inhibition of SEAP activity. Plasma samples collected 2 weeks after the third dose of scSIV were tested for neutralization
(neut.) of SIVmac251LA (A), SIVmac239M5 (B), SIVmac239g123 (C), SIVmac239V1V2 (D), and SIVmac239 (I). Fifty percent neutralization titers
are shown for SIVmac251LA (E), SIVmac239M5 (F), SIVmac239g123 (G), and SIVmac239V1V2 (H). P values were determined by two-tailed
Mann-Whitney U tests. Week 26 plasmas were tested for neutralization of SIVmac239 (J). Plasma samples drawn on week 32 were tested for
neutralization of SIVmac251UCD (K).
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cretions (CVS) of all the immunized animals prior to challenge
(Fig. 4A). Comparison of the specific activity of IgG in CVS
versus plasma revealed a positive correlation (Fig. 4B) (Spear-
man’s r  0.91; P 	 0.0001). This correlation demonstrates
that the proportion of total IgG specific for gp120 in the vag-
inal mucosa closely mirrors the proportion found in plasma.
Indeed, the median ratio of the specific activities in CVS versus
plasma was 1:1 (Fig. 4C). However, the two immunized ani-
mals that remained SIV negative after the 20-week challenge
period had significantly higher prechallenge ratios of specific
activity in CVS versus plasma than the six animals that subse-
quently became infected (Fig. 4C): ratio, 3.6 (95% confidence
interval [CI], 3.1 to 4.0) (P 	 0.001).
gp120-specific IgA was measured in CVS, rectal secretions,
and plasma (Fig. 4D and E). Prior to challenge, none of the
animals had detectable gp120-specific IgA titers in plasma
(data not shown) or CVS (Fig. 4D). Likewise, with the excep-
tion of Mm 305-99, none of the animals had detectable Env-
specific IgA titers in rectal secretions (Fig. 4E). High-titer
gp120-specific IgA responses were observed postinfection in
both CVS and rectal secretions for all six of the scSIV-immu-
nized animals that became infected (Fig. 4D and E).
IgA in CVS, rectal secretions, and plasma was tested for
reactivity against a SIVmac251 viral lysate preparation (Fig. 4F
and G). No IgA specific for viral lysates was detectable in
plasma prior to challenge (data not shown), but low levels were
detectable in CVS from Mm 234-99 (Fig. 4F) and in rectal
secretions from Mm 259-03 and Mm 261-00 (Fig. 4G). High
levels of viral lysate-specific IgA were detectable in CVS and
rectal secretions after infection of all of the immunized animals
(Fig. 4F and G). Thus, the virus-specific IgA detected in some
animals prior to challenge and the high-titer IgA responses
that developed in immunized animals that became infected
may have contributed to the control of viral replication.
FIG. 4. Virus-specific antibody responses were detected in mucosal secretions. Anti-gp120 IgG specific activity (SA) was monitored longitu-
dinally in CVS of immunized animals prior to infection (black), from the week each became infected (blue), and for the two that did not become
infected (green) (A). Mucosal antibody responses in the naïve animals were measured prior to infection (gray) and postinfection (red). The
20-week challenge phase is shaded. The dashed line indicates the limit of detection, defined as the mean plus 3 standard deviations of negative
samples. Anti-gp120 IgG SAs in CVS and plasma are correlated (Spearman’s r 0.91; P	 0.0001) (B). The ratios of anti-gp120 SA in CVS versus
plasma were significantly higher at the five prechallenge time points in the two animals that remained SIV negative (C) (ratio, 3.6; 95% CI, 3.1
to 4.0; P 	 0.001). IgG samples containing readings below the limit of detection, defined as 3 standard deviations above the average SA for naïve
controls, were excluded from correlative and ratio analyses (B and C). IgA SA was monitored against gp120 in CVS (D) and rectal secretions
(E) and against viral lysate in CVS (F) and rectal secretions (G).
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Breadth of virus-specific T-cell responses elicited by immu-
nization with scSIV. T-cell responses to the eight viral antigens
expressed by scSIV were measured longitudinally during the
immunization phase of this experiment by IFN- ELISPOT
assays (Fig. 5). Each animal responded to multiple viral anti-
gens. These responses were boosted by inoculation with VSV
G scSIV on weeks 18 and 24.
The breadth of the CD4 and CD8 T-cell responses elic-
ited by scSIV was assessed by whole-proteome, deconvolution
epitope mapping. CD4 T-cell epitopes were defined on week
25 (Table 2), and CD8 T-cell epitopes were defined on week
26 (Table 3). CD4 T-cell epitopes were analyzed with PBMCs
depleted of CD8 cells by anti-CD8 antibody-coated magnetic
beads, and CD8 T-cell epitopes were analyzed with PBMCs
depleted of CD4 cells by anti-CD4 antibody-coated magnetic
beads. In cases where consecutive 15-mer peptides both scored
positive, the overlapping 11-amino-acid sequence is shown due
to the high probability that a single epitope exists within this
region (Tables 2 and 3). Due to routinely low PBMC yields
from Mm 241-01, a comprehensive analysis of T-cell epitopes
was not possible for this animal. The seven immunized animals
that were mapped recognized an average of 5.4 CD4 and 4.3
CD8 T-cell epitopes. The same methodology was used to
determine that animals chronically infected with live, attenu-
ated SIVmac239nef recognized an average of 5.2 CD4
 T-cell
epitopes (n 5 animals) and 5.2 CD8 T-cell epitopes (n 17
animals) (data not shown). Thus, the breadths of CD4 and
CD8 T-cell responses elicited by scSIV were comparable to
the breadth of T-cell responses elicited by persistent infection
with live, attenuated SIV.
Virus-specific CD8 T cells in peripheral blood and vaginal
mucosa. Immunization with scSIV elicited virus-specific CD8
T cells that were detectable in peripheral blood and the vaginal
mucosa by MHC class I tetramer staining (Fig. 6). Tetramer-
positive CD8 T cells were detected in peripheral blood fol-
lowing the first inoculation in each of the Mamu-A*01- and
-A*02-positive animals, except Mm 305-99. These responses
were boosted by immunization with VSV G scSIV on weeks 18
FIG. 5. T-cell responses were detectable against all proteins expressed by scSIV. IFN- ELISPOT responses against peptide pools of
overlapping 15-mers representing the Gag, Tat, Rev, Vif, Vpr, Vpx, Env, and Nef proteins were measured over the immunization period (weeks
0 to 32). The limit of detection was 50 spot-forming cells (SFCs) per 106 PBMCs.
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and 24. Virus-specific CD8 T-cell responses identified by
tetramer staining mirror the longitudinal IFN- ELISPOT re-
sults (Fig. 5 and 6).
The magnitude of MHC class I tetramer-positive CD8 T-
cell responses elicited by immunization with scSIV varied from
animal to animal. Mm 284-99 had the highest prechallenge
peak responses, with 6.7% of CD8 T cells recognizing Mamu-
A*01 Gag181–189 (CM9) and 2% each of CD8
 T cells recog-
nizing Mamu-A*01 Tat28–35 (SL8) and Mamu-A*02 Nef159–167
(YY9) (Fig. 6D). Mm 305-99 had the lowest-magnitude re-
sponse to Mamu-A*01 Gag181–189 (CM9), which became de-
tectable only after boosting with VSV G scSIV and reached a
maximal frequency of 0.5% of CD8 T cells (Fig. 6C). The
CD8 T-cell response to Mamu-A*01 Tat28–35 (SL8) never
exceeded the limit of detection in this animal. This is consistent
with the absence of T-cell responses to peptides containing this
epitope for both the longitudinal analysis of IFN- ELISPOT
responses to the Tat peptide pool (Fig. 5) and to the individual
15-mer peptides containing this epitope (Table 3). Thus, even
among Mamu-A*01-positive macaques, there was considerable
variation in the magnitude of CD8 T-cell responses elicited
by immunization with scSIV.
SIV-specific CD8 T-cell frequencies were also measured in
lymphocytes isolated from biopsies of the vaginal mucosa on
week 26, 2 weeks after boosting with VSV G scSIV. Tetramer-
positive cell frequencies among lymphocytes isolated from
these biopsies were similar to the frequencies observed in
peripheral blood samples processed in parallel (Fig. 6F). Fre-
quencies of Mamu-A*01 Gag181–189 (CM9)-specific CD8
 T
cells in the biopsies ranged from 0.8% in Mm 305-99 to 3.1%
in Mm 284-99. These biopsy results confirm that intravenous
immunization with scSIV elicited SIV-specific CD8 T cells
that trafficked to the vaginal mucosa and were therefore
present at the site of challenge.
Extraordinarily high anamnestic CD8 T-cell responses en-
sued following infection of immunized animals. Cumulative
Mamu-A*01 Gag181–189 (CM9) plus Mamu-A*01 Tat28–35
(SL8) responses peaked at 22% and 28% of CD8 T cells in
peripheral blood from Mm 259-03 and Mm 261-00, respec-
tively (Fig. 6A and B). Likewise, an astonishing 44% of CD8
T cells recognized the Mamu-A*02 Nef159–167 (YY9) epitope
in Mm 158-02 (Fig. 6E). In contrast, the percentage of Mamu-
A*01 Gag181–189 (CM9)-specific CD8
 T cells declined
steadily in Mm 284-99 from 1.7% to 0.13% of CD8 T cells
during the 20-week challenge period (Fig. 6D). In the case of
Mm 305-99, Mamu-A*01 Gag181–189 (CM9)-specific CD8
 T
cells increased in frequency on weeks 40 to 41 and 46 to 47,
perhaps reflecting the simulation of recall responses by the
challenge virus (Fig. 6C). Robust anamnestic T-cell responses
were observed in the six immunized animals that became in-
fected, but not in the two that remained uninfected.
Outcome of repeated, low-dose vaginal challenge. Repeated,
low-dose vaginal inoculation with SIVmac251UCD was con-
ducted to model heterosexual transmission of HIV-1. Begin-
ning on week 32, each of the eight immunized animals and six
naïve control animals was challenged vaginally with 1,000
TCID50 (1 ng p27) of SIVmac251UCD. Inoculations were ad-
ministered in the morning and again in the afternoon of the
same day each week, for 20 consecutive weeks. Challenge
doses were discontinued when viral RNA was detected in
TABLE 2. CD4 T-cell epitopesa























































a CD4 T-cell epitopes were determined on week 25 by whole-proteome, decon-
volution epitope mapping of CD8-depleted PBMCs. The total numbers of CD4
T-cell epitopes and spot-forming cells (SFCs)/106 PBMCs for each animal are
indicated. The overlapping 11-residue sequence is shown for two consecutive pep-
tides with the higher of the two SFC/106-PBMC numbers.
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plasma for two consecutive weeks for any given animal. All
naïve control animals were expected to become infected (52),
and a significant difference in the number of doses required to
establish infection or in the final number of animals becoming
infected in the immunized group versus the naïve controls
would indicate that immunization prevented transmission. All
six naïve control animals and six of the eight immunized ani-
mals became infected (Fig. 7). Four of the six naïve animals
were infected by a single clone, as determined by single-ge-
nome amplification (SGA) and analysis of sequences encoding
Env at the first viral RNA-positive time point (Eric Hunter,
Emory University, personal communication). A Weibull re-
gression analysis was performed to determine whether the
immunized animals required significantly more doses than the
naïve controls to establish infection. The number of doses
required to establish infection in each group computed a haz-
ard (risk) ratio of 0.38 (95% CI, 0.12 to 1.21), where a ratio of
1 would mean the groups are at equal risk of becoming in-
fected. Although there was a trend toward greater resistance to
infection for the scSIV-immunized animals, this analysis did
not reveal a statistically significant difference in the risk of
infection relative to the control animals (P  0.10).
The repeated, low-dose challenge regimen resulted in ani-
mals becoming infected on different weeks. Viral load mea-
surements were therefore synchronized to the last week in
which viral RNA was undetectable in each animal to compare
differences in peak and set point viral loads (Fig. 8B). All viral
load analyses excluded the two immunized animals that re-
mained uninfected. Peak viral loads were reduced 0.72 log for
the immunized group relative to the control group (Fig. 8C).
The blunting of peak viral loads in the immunized group was
statistically significant (P  0.0038; two-tailed Mann-Whitney
U test). Geometric mean viral loads were 1.1, 1.2, 1.1, and 1.0
log lower on weeks 4, 6, 8, and 12 postinfection in the immu-
nized group relative to the naïve controls. A linear mixed
model analysis of chronic-phase log viral loads also revealed a
statistically significant difference in set point viral loads for the
period between 5 and 67 weeks postinfection, centered on
week 28 (P 0.004) (Fig. 8C). Despite the convergence of viral
loads after week 23 due to the loss of two rapidly progressing
naïve control animals on weeks 16 and 23, viral loads for the
immunized group were 0.96 log lower for this period (95% CI,
0.31 to 1.6). Thus, immunization of macaques according to a
prime-boost regimen with Env-modified and VSV G trans-
complemented scSIV resulted in statistically significant con-
tainment of viral replication.
Despite statistically significant differences in viral loads, im-
munization did not result in significant preservation of CD4
T cells. CD4 T-cell counts in peripheral blood were moni-
tored beginning on the first day of challenge to determine
whether the targets of SIV infection were better protected in
the scSIV-immunized animals (Fig. 9A). Frequencies of naïve,
central memory, and effector memory subsets were defined by
staining for CD28 and CD95 (Fig. 9B to D). CD4 T cells were
also stained for CCR5 to identify this specific target population
(Fig. 9E). Although memory CD4 T cells in the immunized
animals appeared to persist at higher levels during acute in-
fection, differences in CD4 T-cell counts between the groups
were not significant (Fig. 9C, D, and E). Therefore, although
immunization reduced viral loads, this statistically significant
TABLE 3. CD8 T-cell epitopesa
Macaque





Nef QDYTSGPGIRY A*02 Nef YY9 1,919
Vif WTDVTPNYADI A*02 Vif VI8 529
Gag PTGSENLKSLY A*02 Gag GY9 386
Pol WMGYELWPTKWKLQK Undefined 90
Total 4 2,924
Mm 234-99
Env VFGNWFDLASW Undefined 1,478
Vpr FRGGCIHSRIG Undefined 934
Nef SGPGIRYPKTFGWLW A*02 Nef YY9 314
Vpr DEWVVEVLEELKEEA Undefined 73
Env KERDGGEGGGNSSWP Undefined 73
Vif TPNYADILLHSTYFP A*02 Vif YY10 61
Vif WAWWTCSRVIFPLQE Undefined 61
Total 7 2,994
Mm 259-03
Gag CTPYDINQMLN A*01 Gag CM9 1,939
Tat ADASTPESANL A*01 Tat SL8 590
Vpx SGEETIGEAFE Undefined 305
Env CLPDNGDYSEVALNV Undefined 118
Env GTTQCLPDNGDYSEV Undefined 80
Total 5 3,032
Mm 261-00
Gag CTPYDINQMLN A*01 Gag CM9 1,305
Tat ADASTPESANL A*01 Tat SL8 1,259
Env CAPPGYALLRCNDTN A*01 Env CL9 119
Total 3 2,683
Mm 284-99
Gag CTPYDINQMLN A*01 Gag CM9 2,227
Nef QDYTSGPGIRY A*02 Nef YY9 235
Tat ADASTPESANL A*01 Tat SL8 178
Total 3 2,640
Mm 305-99
Gag CTPYDINQMLN A*01 Gag CM9 295
Rev TDTPLDLAIQQLQNL Undefined 145
Gag QRHLVVETGTTETMP Undefined 123
Env VPWPNASLTPKWNNE A*01 Env TL9 91
Total 4 654
Mm 316-98
Gag LDRFGLAESLL Undefined 1,599
Gag DRQAGFLGLGPWGKK Undefined 216
Gag AKCPDRQAGFLGLGP Undefined 146
Nef RSRPSGDLRQRLLRA Undefined 76
Total 4 2,037
a CD8 T-cell epitopes were determined on week 26 by whole-proteome,
deconvolution epitope mapping of CD4-depleted PBMCs. The total number of
CD8 T-cell epitopes and spot-forming cells (SFCs) per 106 PBMCs for each
animal are indicated. The overlapping 11-residue sequence is shown for two
consecutive peptides with the higher of the two SFC/106-PBMC numbers.
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reduction did not appear to translate into significant differ-
ences in CD4 T-cell counts in peripheral blood.
DISCUSSION
Stimulation of effective T-cell and antibody responses is
likely to be essential for achieving protection against HIV-1.
As an experimental vaccine approach designed to elicit broad
T-cell responses plus antibodies to the native conformation of
the viral envelope glycoprotein as it exists on virions, we de-
veloped a technique for producing strains of SIV that are
limited to a single cycle of infection (27, 28, 39). Immunization
of rhesus macaques with scSIV stimulated robust virus-specific
T-cell responses and significantly reduced viral replication fol-
lowing an intravenous challenge with SIVmac239 (39). While
scSIV also elicited low-titer Env-specific antibodies capable of
FIG. 7. Animals were challenged by repeated, low-dose vaginal
inoculation. The eight immunized animals (blue) and six naïve controls
(red) were challenged vaginally with 1 ng p27 (1,000 TCID50) of
SIVmac251UCD for 20 weeks, beginning on week 32. Virus was admin-
istered twice on the days of challenge—once in the morning and again
in the afternoon—on the same day each week. All six naïve control
animals became infected by the 11th week of challenge, but two of the
eight immunized animals remained uninfected after the 20th week.
FIG. 6. Virus-specific CD8 T cells were detected in peripheral blood and the vaginal mucosa. CD8 T cells binding the MHC class I tetramers
Mamu-A*01 Gag181–189 (CM9), Mamu-A*01 Tat28–35 (SL8), Mamu-A*02 Nef159–167 (YY9), and Mamu A*02 Gag71–79 (GY9) were detected in
peripheral blood (A to E). The limit of detection indicated by the dotted line is 0.05% of CD8 T cells. The 20-week challenge period is shaded.
Tetramer-positive CD8 T-cell frequencies are shown prior to infection (black) and from the week each animal became infected (blue) (A, B, and
E). Frequencies of tetramer-positive CD8 T cells are shown for the two immunized animals that remained uninfected (green) (C and D). Similar
frequencies of CD8 T cells were tetramer positive among lymphocytes isolated from vaginal biopsies versus peripheral blood (F).
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neutralizing lab-adapted SIVmac251LA, these antibody re-
sponses were unable to detectably neutralize SIVmac239 (39).
In an effort to enhance Env-specific antibody responses and
the extent of protection afforded by scSIV, we immunized
macaques with Env-modified strains of scSIV lacking specific
structural features thought to interfere with the induction of
neutralizing antibodies.
Immunization with Env-modified scSIV facilitated the de-
velopment of antibodies to epitopes accessible in Envs lacking
the three N-linked glycans in gp41 or 100 amino acids in the
V1V2 region of gp120. However, none of the animals detect-
ably neutralized SIVmac239 or SIVmac251UCD. Therefore, the
antibodies responsible for the enhanced neutralization of the
g123 and V1V2 Envs may have recognized surfaces that are
not accessible on wild-type virions. Alternatively, a subset of
these antibodies may have interacted with the wild-type Envs
but bound with an affinity too low to detect neutralization.
Likewise, antibodies capable of binding wild-type Envs may
have been present but were produced at concentrations too
low to block infectivity. However, the induction of antibodies
that detectably neutralize these strains, in the absence of per-
sistent infection by a replicating virus, would have been un-
precedented. Although no animals detectably neutralized the
challenge strain, we cannot exclude the possibility that anti-
bodies may have contributed to protection through mecha-
nisms other than neutralization, such as antibody-dependent
cell-mediated cytotoxicity (ADCC), antibody-dependent cell-
mediated viral inhibition (ADCVI) (32), complement fixation,
and clearance of opsonized virus.
Antibodies present in mucosal secretions were measured
due to their potential importance in preventing sexual trans-
mission of HIV-1. Immunization elicited gp120-specific IgG
that was detectable in the CVS of all of the animals and
appeared to be in equilibrium with the plasma in most cases.
Therefore, virus-specific IgG would be expected to be present
in CVS for any immunization strategy that elicits virus-specific
IgG in plasma. In contrast, virus-specific IgA was not efficiently
elicited. Prior to challenge, none of the animals had detectable
gp120-specific IgA in CVS, and low-titer gp120-specific IgA
was detectable in the rectal secretions of only one immunized
animal, Mm 305-99. Despite having low to undetectable levels
of virus-specific IgA prior to challenge, all of the immunized
animals that became infected developed high-titer IgA re-
sponses capable of binding to gp120 and to whole-virus lysate.
These high IgA titers are consistent with postchallenge anam-
nestic responses primed by immunization. Alternatively, the
capacity of the immunized animals to mount high-titer virus-
specific IgA responses after becoming infected may be an effect
of immunological containment of viral replication.
T-cell responses measured by IFN- ELISPOT and MHC
class I tetramer staining were similar in magnitude to re-
sponses elicited by prime-boost vaccine regimens employing
recombinant DNA and/or viral vectors (3, 16, 36, 68, 73, 78).
Virus-specific CD8 T-cell frequencies among lymphocytes
FIG. 8. Postchallenge plasma viral RNA loads. Viral loads were measured at weekly intervals beginning on week 32 using a real-time RT-PCR
assay with a limit of detection of 30 copies of RNA per ml of plasma for the immunized animals that became infected (blue) or remained uninfected
(green) and for the naïve controls (red) (A) (19). Viral load measurements were synchronized to the last week in which viral RNA was undetectable
in each animal that became infected (B). Comparison of geometric mean viral loads for the infected animals revealed acute peak viremia was
reduced by 0.72 log (P  0.0038; two-tailed Mann-Whitney U test) and was lower by 1.1, 1.2, 1.1, and 1.0 log on weeks 4, 6, 8, and 12 in the
immunized group (C). Set point viral loads were significantly reduced for the period between weeks 5 and 67 postinfection, centered on week 28,
as determined by a mixed linear model analysis (P 0.004; 0.96 log lower; 95% CI, 0.31 to 1.6). Due to progression to AIDS, naïve control animals
Mm 230-04, Mm 215-98, Mm 358-01, and Mm 128-01 were euthanized weeks 16, 23, 43, and 51 postinfection, and immunized animals Mm 316-98
and Mm 158-02 were euthanized 38 and 44 weeks postinfection.
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isolated from the vaginal mucosa were similar to frequencies in
peripheral blood. Thus, immunization with scSIV elicited T-
cell responses that trafficked to the vaginal mucosa and were
present at the site of challenge. Deconvolution epitope map-
ping identified means of 5.4 CD4 and 4.3 CD8 T-cell
epitopes per animal, which was similar to the breadth of re-
sponses elicited by persistent infection with live, attenuated
SIV. Therefore, immunization with scSIV elicited high-fre-
quency virus-specific T cells that recognized multiple viral an-
tigens and trafficked to the vaginal mucosa.
Protection was assessed by repeated, low-dose vaginal inoc-
ulation with SIVmac251UCD to model heterosexual transmis-
sion of HIV-1. Although there appeared to be a trend toward
a greater number of challenge doses required to establish in-
fection for the immunized animals, this trend was not statisti-
cally significant (P 0.10; hazard ratio of 0.38, 95% CI, 0.12 to
1.21). However, peak and set point viral loads were signifi-
cantly lower in the six immunized animals that became infected
relative to the naïve controls. Peak viral loads were reduced by
0.72 log (P 0.0038), and set point viral loads were reduced by
approximately 1 log for the period between 5 and 67 weeks
postinfection (P  0.004; 0.96 log lower; 95% CI, 0.31 to 1.6).
Geometric mean viral loads converged after 23 weeks postin-
fection, due to the loss and subsequent exclusion of the two
control animals with the highest viral loads.
The SIVmac251UCD challenge strain appears to be particu-
larly difficult to protect against by immunization, perhaps even
more so than SIVmac239. Differences in peak and set point
viral loads in the immunized animals relative to the naïve
controls were not as great as those previously observed follow-
ing intravenous challenge with SIVmac239 (39). Moreover, de-
spite the partial containment of viral replication in the immu-
nized animals, we did not observe better preservation of CD4
T cells. It is possible that genetic differences between
SIVmac239 and the SIVmac251UCD challenge stock (52) may
have been responsible for this difference in protection. The
virus stock of SIVmac251UCD utilized for repeated, low-dose
vaginal challenge in this study was derived from the original
SIVmac251 isolate by passage of acute-phase virus through
animals and selection of virus cultures with the fastest growth
kinetics on rhesus macaque PBMCs (52). This process may
have favored the selection of more fit or more pathogenic
variants. Furthermore, two amino acids in Env that consis-
tently revert in animals infected with SIVmac239 (15) differ
from the SIVmac251UCD challenge stock (data not shown).
These, plus additional differences including suboptimal nucle-
otides at positions elsewhere in the SIVmac239 genome (1),
might explain why it appears to be more difficult to protect
against SIVmac251UCD than SIVmac239.
Two immunized animals, Mm 284-99 and Mm 305-99, re-
mained uninfected after 20 weeks of repeated vaginal chal-
lenge with SIVmac251UCD. Inherent genetic differences in the
capacity to support SIV replication could explain why these
two animals remained uninfected. However, there is no evidence
that these animals had reduced inherent capacity to support SIV
infection, since peak viral loads following the first dose of scSIV
FIG. 9. CD4 T-cell populations postinfection. CD4 T-cell counts were synchronized to the last week in which viral RNA was undetectable
for each animal. The numbers of total CD3 CD4 (A), CD3 CD4 CD28 CD95 naïve (B), CD3 CD4 CD28 CD95 central memory (C),
CD3 CD4 CD28 CD95 effector memory (D), and CD3 CD4 CCR5 CD95 memory (E) T cells per l of whole blood were monitored.
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were similar in magnitude among all of the immunized animals.
Furthermore, these animals were not resistant to a subsequent
intravenous challenge with SIVmac251UCD. Nevertheless, it is
possible that genetic factors underlie differences in the T-cell
and antibody responses stimulated in these animals by immu-
nization with scSIV. Both animals possessed the protective
MHC class I allele Mamu-A*01 (57, 58), and Mm 284-99 had
the highest virus-specific T-cell responses in the vaginal mu-
cosa at week 26 and in the peripheral blood at the beginning of
the challenge period. Antibody responses in these two animals
also appeared to differ from those in the six immunized
animals that became infected. Mm 284-99 neutralized
SIVmac239g123 at a titer nearly 200-fold higher than the aver-
age for the rest of the group and 80-fold higher than the next
highest animal. Moreover, neutralization of SIVmac251UCD ap-
proached a 50% reduction in infectivity at a 1:8 dilution of
plasma from Mm 284-99 collected at the beginning of the
challenge period. In addition, Mm 284-99 also had the highest
anti-gp120 IgG-specific activity in cervicovaginal secretions at
four of five time points prior to challenge. Both Mm 284-99
and Mm 305-99 also had higher prechallenge ratios of anti-
gp120 IgG-specific activity in cervicovaginal secretions versus
plasma (ratio, 4.0; 95% CI, 2.6 to 6.0; P 	 0.01), perhaps
reflecting local overproduction of gp120-specific IgG by B cells
residing in the cervicovaginal mucosa (14, 61, 62). Also, the
only animal that had detectable gp120-specific IgA prior to
challenge was Mm 305-99. Hence, there were a number of
qualitative and quantitative differences in the T-cell and anti-
body responses that may have contributed to the absence of
SIV infection in Mm 284-99 and Mm 305-99.
The partial containment of SIV replication afforded by T-
cell-based vaccines has thus far failed to provide adequate
protection against immunodeficiency virus infection (12, 16,
36, 49, 54, 58, 73). Neutralizing antibodies can prevent the
acquisition of viral infection (6, 33, 34, 53, 59), but eliciting
such antibodies is a daunting challenge due to structural and
thermodynamic properties of the envelope glycoprotein that
render it resistant to antibodies (17, 46, 47, 64, 71, 75, 79, 83,
85). However, a strategy that elicits effective antibody re-
sponses to the viral envelope glycoprotein may be a necessary
component of any protective vaccine against HIV-1. In this
study, we tested the hypothesis that removal of specific struc-
tural features thought to interfere with the induction of neu-
tralizing antibodies might facilitate their development. Despite
significantly enhancing antibody responses to epitopes re-
vealed by the removal of the V1V2 loops or the three N-linked
glycans in gp41, neutralizing activity against SIVmac239 and
SIVmac251UCD remained undetectable. Nevertheless, two im-
munized animals remained uninfected after a 20-week period
of repeated, low-dose vaginal challenge in which all of the
naïve control animals became infected. The six immunized
animals that ultimately became infected had significantly lower
peak and set point viral loads relative to the naïve control
animals. The two that remained uninfected appeared to differ
in several prechallenge measures of T-cell and antibody re-
sponses. These results are particularly intriguing in light of
recent evidence that Env-specific antibodies contributed to the
modest decrease in the incidence of HIV-1 infection observed
among participants in an HIV-1 vaccine phase III clinical trial
of a prime-boost regimen based on a recombinant canarypox
vector and soluble gp120 protein (65).
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